Partnerships Develop New Drugs for Third-World Nations - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Partnerships Develop New Drugs for Third-World Nations
New collaborative research models plus industry mindset yield treatments for neglected diseases.


Pharmaceutical Technology



Jill Wechsler
During the past few years, it has become good business and good politics for pharmaceutical companies to invest in the research and development (R&D) of drugs and vaccines to treat a host of deadly diseases plaguing the poorer nations of the world. The Bill and Melinda Gates Foundation deserves much credit for putting this important issue at the top of the agenda for donor nations, nonprofit organizations, and pharmaceutical manufacturers. The spread of the AIDS epidemic around the world and the looming pandemic flu crisis have brought home the threat of health problems in distant continents, prompting wealthy governments to focus more on global biomedical research and treatment programs.

The challenges for pharmaceutical manufacturers are considerable. The industry's high profits and research successes boost pressure to devote more corporate resources to third-world medical needs. But, such initiatives often require new skills and knowledge and need different procedures for conducting research. Despite much public attention, the level of support from national governments remains fairly meager and uncertain.

In the past, pharmaceutical companies often gave away available drugs for third-world diseases, but this has not encouraged investment in research on needed treatments that have little market value in industrial states. A more recent strategy has been to establish artificial commercial markets. US and European governments have offered tax breaks and patent extensions to push R&D. They also have provided advance purchase commitments (APCs) to "pull" new products to market. But, analysts now consider these tactics only minimally effective because they often yield treatments with low value for patients in poor countries. Some products still are too expensive for widespread purchase and have dosing and distribution requirements that undermine access and compliance.

New landscape


Promoting global drug quality oversight
Although governments and international agencies continue to back the push–pull drug development model, there is growing support for new partnership arrangements that aim to speed drug research by reducing the risk for pharmaceutical companies. This approach has altered the landscape for developing new drugs to treat neglected diseases, according to an important study by a research group at the London School of Economics headed by Mary Moran, MD. Published in September 2005 by the Wellcome Trust, the report documents how public–private partnerships (PPPs) during the past five years have spurred R&D on new treatments for third-world health conditions such as malaria, tuberculosis (TB), leprosy, leishmaniais, schistosomiasis, dengue fever, and others.*

Although pharmaceutical companies developed only a handful of new drugs to treat neglected diseases in the previous 25 years, Moran finds that from 2000 to 2004, partnerships involving large and small companies and nonprofit organizations launched 63 research projects that should translate into nine or 10 new drugs by 2010. This investment has occurred largely outside normal government health funding programs and has been supported substantially by Gates, the Rockefeller Foundation, and other private donors.

In the 1990s, multinational pharmaceutical companies closed down neglected disease research, according to Moran. Now, they are joining PPPs such as Medicines for Malaria Venture, the TB Alliance, Drugs for Neglected Diseases, and the Institute for OneWorld Health (iOWH) and investing their own resources in this area to address objectives such as:

  • reaching major emerging markets in India and China and gaining access to highly skilled researchers through partnerships with local pharmaceutical companies;
  • deflecting criticism over industry's failure to address the global HIV–AIDS pandemic as well as life-threatening diseases not found in Western nations;
  • eventually developing spin-off products with commercial value in Western markets.

In addition, a growing number of niche biotechnology companies regard small infectious disease markets similarly to orphan drug development. R&D partnerships provide the means for many small companies to parlay expertise in genomics, bioinformatics, and other innovative technologies into new development programs and also to license out intellectual property to larger partners.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here